Biotekfirma overvejer børs eller aktiesalg til kapitalfond

Det svenske biotekselskab Asarina Pharma med dank biotekprofil i spidsen står over for en kommende kapitalrejsning. Firmaet er i dialog med kapitalfond om investering, men overvejer også børsnotering.
AF MIKKEL AABENHUS HEMMINGSEN

Det svenske børsmarked har godt fat i life science-industrien, og alene i 2017 kiggede 36 selskaber mod børserne i Sverige i deres jagt på risikovillig kapital.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Further reading